Keyphrases
Multiple Myeloma Patients
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Ulcerative Colitis
66%
Robarts Histopathology Index
59%
Remission
47%
Multiple Myeloma
41%
Disease Activity
40%
Confidence Interval
37%
Newly Diagnosed multiple Myeloma
37%
Certolizumab Pegol
33%
Design Protocol Analysis
33%
Colon Biopsy
33%
Clinical Prediction Model
33%
Crohn's Disease
33%
Vacutainer
33%
Risk Stratification
33%
Long-term Responders
33%
Revised International Staging System
33%
Immune Markers
33%
Standard Risk
33%
Moderate to Severe
33%
Disease Activity Score
33%
Winning Probability
33%
Mayo Clinic Score
33%
Severe Ulcerative Colitis
33%
Multivariable
26%
Tolerance Interval
25%
Complete Response
20%
Odds Ratio
19%
Progression-free Survival
16%
Retrospective Analysis
15%
α-Chain
14%
Index Score
14%
Ustekinumab
13%
Placebo
13%
Active Ulcerative Colitis
13%
Very Good Partial Response
12%
Lenalidomide
12%
Post-transplant Management
12%
Median Overall Survival
12%
Median Progression-free Survival
11%
International Staging System
11%
Simple Tools
11%
Hazard Ratio
11%
Prognostic Tool
11%
Gold Nanoparticles Coating
11%
CD-8
9%
CD103
9%
HLA-DR
9%
Forkhead Box P3 (FOXP3)
9%
Medicine and Dentistry
Ulcerative Colitis
100%
Multiple Myeloma
100%
Autologous Hematopoietic Stem Cell Transplantation
100%
Progression Free Survival
50%
Patient with Ulcerative Colitis
38%
Post-Hoc Analysis
38%
Disease Activity
37%
Risk Stratification
33%
Pediatrics
33%
Retrospective Cohort Study
33%
Interim Analysis
33%
Crohn's Disease
33%
Biopsy Technique
33%
Transplantation
33%
Infliximab
33%
Overall Survival
27%
Diseases
14%
Rectal Bleeding
13%
Lenalidomide
12%
Histopathology
12%
Patient with Crohn's Disease
11%
Pediatrics Patient
11%
Immunoglobulin Producing Cell
11%
Retrospective Study
11%
Autologous Stem Cell Transplantation
11%
Disease Exacerbation
11%
Ustekinumab
9%
Placebo
9%
Hazard Ratio
8%
Minimal Residual Disease
8%
Dexamethasone
8%
Odds Ratio
7%
Crohn's Disease Activity Index
7%
Proportional Hazards Model
6%
Randomized Controlled Trial
6%
Endoscopy
6%
Observational Study
6%
Vedolizumab
6%
Immunology and Microbiology
Multiple Myeloma
66%
Autologous Hematopoietic Stem Cell Transplantation
66%
Progression Free Survival
50%
Ulcerative Colitis
46%
Immunocompetent Cell
40%
Cell Marker
33%
Cell Isolation
33%
Crohn's Disease
33%
Infliximab
33%
Peripheral Blood Mononuclear Cell
33%
Overall Survival
27%
CD8
22%
Cell Viability
20%
T Cell
20%
Alpha Chain
19%
Cell Composition
13%
Lenalidomide
12%
CD4
11%
Immunoglobulin Producing Cell
11%
Autologous Stem Cell Transplantation
11%
Human Leukocyte Antigen
9%
CD20
9%
CD68
9%
Lymphocyte Activation
9%
CD19
9%
Dexamethasone
8%
Centrifugation
6%
Cell Count
6%
Data Processing
6%
T-Helper Cell
6%
